Dubbed “DARE-19”, AstraZeneca said on Thursday that the study will assess if Farxiga can reduce the risk of death from serious complications and organ failure in such patients. “AstraZeneca is committed to finding new solutions to fight COVID-19 by investigating the application of our new and existing medicines,” Mene Pangalos, Executive VP of biopharmaceuticals at the company, said. While existing medications being trialled include cancer drugs and immunotherapies, some research shows that patients with existing heart conditions are at a high risk of developing COVID-19 complications, including heart failure.
